Elsevier announces first-ever journal of nanomedicine

Nanomedicine: Nanotechnology, Biology and Medicine to launch in March 2005.

St. Louis, MO, January 17, 2005 - Elsevier, the world-leading scientific and medical publisher, announces plans to launch the world's first peer-reviewed journal devoted to nanomedicine - the emerging science of using molecular machines to treat human disease. Nanomedicine: Nanotechnology, Biology, and Medicine, the official publication of the American Academy of Nanomedicine, will be published quarterly, with the first issue to appear in March 2005.

“Nanomedicine has developed very rapidly in recent years, with promising applications in areas such as recognition of cancer cells, stem cell labeling, and monitoring of DNA damage and repair," says Dr. Chiming Wei of Johns Hopkins University School of Medicine, the new journal’s Editor-in-Chief. "We hope this journal will provide a new focal point for efforts to advance this revolutionary technology for maintaining and restoring human health."

Nanomedicine will be the first professional journal devoted solely to the medical uses of nanotechnology, bringing together experts from every scientific field involved in this new science. The journal will select and publish the most important papers in basic and clinical nanomedicine, diagnostic advances and applications, pharmacologic nanomedicine, engineering and biotechnology for clinical applications, and more.

Nanomedicine will also include up-to-date reviews of specific topic areas, reports on new equipment and techniques, and regular features on the commercialization of nanomedicine, ethics in the field of nanomedicine, and funding opportunities for nanomedicine research. In addition to original studies, first issue highlights include an essay by Robert A. Freitas, Jr., entitled "What Is Nanomedicine?" as well as an article on "The Pathway to Commercialization for Nanomedicine," coauthored by Dr. Wei.

Subscribers will have full access to each issue on the journal’s website, www.nanomedjournal.com. Nanomedicine will also be accessible through Elsevier's ScienceDirect, the world's largest electronic collection of science, technology and medicine full text and bibliographic information.

"Emerging technologies such as nanotechnology and MEMS (Micro-Electro-Mechanical Systems) and materials, for example, biocompatible polymers and nanoparticles provide many promising opportunities for developing new drugs and innovative treatment methods to improve patients’ quality of life," observes Tachung C. Yih, Ph.D., of University of Texas at San Antonio, Nanomedicine’s Executive Editor. "The development of nanomedicine offers potential advantages over conventional medicine in terms of miniaturized size, implantability, portability, and efficacy. This landmark scientific publication will serve as a “journal of record” for the rapid advances taking place in this arena around the world."

# # #

About the American Academy of Nanomedicine
The American Academy of Nanomedicine (AANM) is an international society created to advance research and clinical applications in the field of nanomedicine. AANM is the only society devoted specifically to the emerging field of nanomedicine. The Society’s membership includes basic and clinical investigators, engineers, molecular biologists, physicians, and others with an interest in the field. AANMprovides a forum to exchange ideas, communicate new findings, and encourage collaboration among the diverse disciplines represented in nanomedicine.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com